

**TCu 380A continuation at 12 months post-insertion – sensitivity analysis**

<b>Subgroup 1 (Nulliparous women aged &lt;30 years)</b>	<b>(81.60% (95% CI 76.52-86.21%))</b>
Excluding Abraham et al. (<20)	82.04% (95% CI 76.48-87.04%)
Excluding Abraham et al. (20-25)	78.01% (95% CI 66.60-87.74%)
Excluding Hall and Kutler (18-30)	81.83% (95% CI 76.66-86.49%)
<b>Subgroup 2 (Nulliparous women of any age)</b>	<b>(80.97% (95% CI 76.04-85.48%))</b>
Excluding Abraham et al. (>25)	81.99% (95% CI 79.19-84.63%)
Excluding Akintomide et al. (15-37)	81.94% (95% CI 79.41-84.34%)
Excluding Roy et al. (14-33)	80.12% (95% CI 73.92-85.70%)
<b>Overall effect size (all studies)</b>	<b>(81.93% (95% CI 79.66-84.09%))</b>
Excluding Abraham et al. (<20)	81.84% (95% CI 79.13-84.40%)
Excluding Abraham et al. (20-25)	81.44% (95% CI 78.16-84.53%)
Excluding Hall and Kutler (18-30)	81.87% (95% CI 79.60-84.03%)
Excluding Abraham et al. (>25)	81.57% (95% CI 78.38-84.58%)
Excluding Akintomide et al. (15-37)	82.14% (95% CI 79.87-84.31%)
Excluding Roy et al. (14-33)	80.92% (95% CI 76.93-84.64%)

**TCu 200 continuation at 12 months post-insertion – sensitivity analysis**

<b>Subgroup 1 (Nulliparous women aged &lt;30 years)</b>	<b>(73.03% (95% CI 67.63-78.10%))</b>
Excluding Lewit (15-19)	75.26% (95% CI 73.90-76.59%)
Excluding Lewit (20-24)	73.33% (95% CI 71.62-75.00%)
Excluding Lewit (25-29)	71.78% (95% CI 70.30-73.24%)
<b>Subgroup 2 (Nulliparous women of any age)</b>	<b>(76.51% (95% CI 72.67-80.14%))</b>
Excluding Roy et al. (14-33)	76.83% (95% CI 72.49-80.91%)
Excluding Luukkainen et al. (19-35)	76.53% (95% CI 71.86-80.91%)
Excluding Larsen et al. (15-44)	76.85% (95% CI 72.79-80.67%)
Excluding Ostergard and Gunning (18-34)	76.84% (95% CI 72.76-80.69%)
Excluding Lewit (30-34)	75.59% (95% CI 71.42-79.54%)
Excluding Lewit (35-49)	75.20% (95% CI 71.98-78.29%)
Excluding Liedholm and Sioberg (14-40)	77.32% (95% CI 73.40-81.01%)
Excluding Mishell et al. (14-33)	76.84% (95% CI 72.51-80.91%)
<b>Overall effect size (all studies)</b>	<b>(75.44% (95% CI 72.32-78.43%))</b>
Excluding Lewit (15-19)	76.43% (95% CI 73.71-79.04%)
Excluding Lewit (20-24)	75.59% (95% CI 71.81-79.17%)
Excluding Lewit (25-29)	76.16% (95% CI 71.60-78.56%)
Excluding Roy et al. (14-33)	75.56% (95% CI 72.16-78.81%)
Excluding Luukkainen et al. (19-35)	75.38% (95% CI 71.89-78.72%)
Excluding Larsen et al. (15-44)	75.60% (95% CI 72.34-78.70%)
Excluding Ostergard and Gunning (18-34)	75.59% (95% CI 72.33-78.71%)
Excluding Lewit (30-34)	74.72% (95% CI 71.59-77.73%)

Excluding Lewit (35-49)	74.37% (95% CI 71.53-77.10%)
Excluding Liedholm and Sioberg (14-40)	75.87% (95% CI 72.61-78.98%)
Excluding Mishell et al. (14-33)	75.56% (95% CI 72.16-78.81%)

#### TCu 200 discontinuation at 12 months due to pain/bleeding – sensitivity analysis

<b>Subgroup 1 (Nulliparous women aged &lt;30 years)</b>	<b>(7.05% (95% CI 5.59-8.65%))</b>
Excluding Lewit (15-19)	7.31% (95% CI 6.52-8.14%)
Excluding Lewit (20-24)	6.31% (95% CI 5.41-7.27%)
Excluding Lewit (25-29)	7.88% (95% CI 7.02-8.78%)
<b>Subgroup 2 (Nulliparous women of any age)</b>	<b>(12.77% (95% CI 8.48-17.78%))</b>
Excluding Roy et al. (14-33)	13.10% (95% CI 8.10-19.06%)
Excluding Luukkainen et al. (19-35)	11.02% (95% CI 8.41-13.92%)
Excluding Larsen et al. (15-44)	12.40% (95% CI 7.87-17.76%)
Excluding Ostergard and Gunning (18-34)	12.86% (95% CI 8.20-18.35%)
Excluding Lewit (30-34)	13.61% (95% CI 8.83-19.22%)
Excluding Lewit (35-49)	13.79% (95% CI 9.10-19.25%)
Excluding Liedholm and Sioberg (14-40)	12.08% (95% CI 7.56-17.45%)
Excluding Mishell et al. (14-33)	13.13% (95% CI 8.13-19.08%)
<b>Overall effect size (all studies)</b>	<b>(10.87% (95% CI 7.98-14.15%))</b>
Excluding Lewit (15-19)	11.37% (95% CI 8.08-15.12%)
Excluding Lewit (20-24)	11.23% (95% CI 7.70-15.32%)
Excluding Lewit (25-29)	11.52% (95% CI 8.34-15.14%)
Excluding Roy et al. (14-33)	10.90% (95% CI 7.77-14.47%)
Excluding Luukkainen et al. (19-35)	9.32% (95% CI 7.62-11.17%)
Excluding Larsen et al. (15-44)	10.51% (95% CI 7.58-13.86%)
Excluding Ostergard and Gunning (18-34)	10.78% (95% CI 7.77-14.20%)
Excluding Lewit (30-34)	11.23% (95% CI 8.01-14.92%)
Excluding Lewit (35-49)	11.34% (95% CI 8.17-14.94%)
Excluding Liedholm and Sioberg (14-40)	10.26% (95% CI 7.40-13.53%)
Excluding Mishell et al. (14-33)	10.92% (95% CI 7.78-14.50%)

#### TCu 200 discontinuation at 12 months due to expulsion – sensitivity analysis

<b>Subgroup 1 (Nulliparous women aged &lt;30 years)</b>	<b>(10.52% (95% CI 7.17-14.41%))</b>
Excluding Lewit (15-19)	8.59% (95% CI 7.74-9.48%)
Excluding Lewit (20-24)	11.21% (95% CI 10.03-12.44%)
Excluding Lewit (25-29)	10.36% (95% CI 9.38-11.38%)
<b>Subgroup 2 (Nulliparous women of any age)</b>	<b>(4.93% (95% CI 2.93-7.39%))</b>
Excluding Roy et al. (14-33)	4.85% (95% CI 2.57-7.78%)
Excluding Luukkainen et al. (19-35)	4.17% (95% CI 2.68-5.96%)
Excluding Larsen et al. (15-44)	4.92% (95% CI 2.79-7.58%)
Excluding Ostergard and Gunning (18-34)	4.80% (95% CI 2.69-7.46%)
Excluding Lewit (30-34)	4.74% (95% CI 2.41-7.76%)
Excluding Lewit (35-49)	5.24% (95% CI 3.03-7.99%)
Excluding Liedholm and Sioberg (14-40)	5.84% (95% CI 3.95-8.07%)

Excluding Mishell et al. (14-33)	4.85% (95% CI 2.57-7.77%)
<b>Overall effect size (all studies)</b>	<b>(6.44% (95% CI 4.49-8.69%))</b>
Excluding Lewit (15-19)	5.76% (95% CI 4.14-7.61%)
Excluding Lewit (20-24)	6.16% (95% CI 3.87-8.93%)
Excluding Lewit (25-29)	6.16% (95% CI 3.96-8.79%)
Excluding Roy et al. (14-33)	6.55% (95% CI 4.47-8.99%)
Excluding Luukkainen et al. (19-35)	6.01% (95% CI 3.98-8.42%)
Excluding Larsen et al. (15-44)	6.54% (95% CI 4.51-8.91%)
Excluding Ostergard and Gunning (18-34)	6.46% (95% CI 4.43-8.83%)
Excluding Lewit (30-34)	6.47% (95% CI 4.36-8.95%)
Excluding Lewit (35-49)	6.87% (95% CI 4.87-9.18%)
Excluding Liedholm and Sioberg (14-40)	7.29% (95% CI 5.39-9.45%)
Excluding Mishell et al. (14-33)	6.55% (95% CI 4.47-8.99%)

#### TCu 200 discontinuation at 12 months due to pregnancy – sensitivity analysis

<b>Subgroup 1 (Nulliparous women aged &lt;30 years)</b>	<b>(2.19% (95% CI 1.47-3.05%))</b>
Excluding Lewit (15-19)	2.27% (95% CI 1.82-2.75%)
Excluding Lewit (20-24)	1.83% (95% CI 1.35-2.39%)
Excluding Lewit (25-29)	2.63% (95% CI 2.13-3.18%)
<b>Subgroup 2 (Nulliparous women of any age)</b>	<b>(1.15% (95% CI 0.54-1.95%))</b>
Excluding Roy et al. (14-33)	1.07% (95% CI 0.40-1.99%)
Excluding Luukkainen et al. (19-35)	0.96% (95% CI 0.38-1.75%)
Excluding Larsen et al. (15-44)	1.18% (95% CI 0.53-2.05%)
Excluding Ostergard and Gunning (18-34)	1.31% (95% CI 0.65-2.16%)
Excluding Lewit (30-34)	1.35% (95% CI 0.70-2.18%)
Excluding Lewit (35-49)	1.31% (95% CI 0.62-2.20%)
Excluding Liedholm and Sioberg (14-40)	1.00% (95% CI 0.42-1.78%)
Excluding Mishell et al. (14-33)	1.07% (95% CI 0.40-1.99%)
<b>Overall effect size (all studies)</b>	<b>(1.49% (95% CI 0.96-2.13%))</b>
Excluding Lewit (15-19)	1.39% (95% CI 0.81-2.09%)
Excluding Lewit (20-24)	1.34% (95% CI 0.83-1.94%)
Excluding Lewit (25-29)	1.48% (95% CI 0.87-2.22%)
Excluding Roy et al. (14-33)	1.46% (95% CI 0.89-2.16%)
Excluding Luukkainen et al. (19-35)	1.40% (95% CI 0.83-2.09%)
Excluding Larsen et al. (15-44)	1.53% (95% CI 0.98-2.19%)
Excluding Ostergard and Gunning (18-34)	1.62% (95% CI 1.07-2.26%)
Excluding Lewit (30-34)	1.69% (95% CI 1.18-2.29%)
Excluding Lewit (35-49)	1.64% (95% CI 1.10-2.28%)
Excluding Liedholm and Sioberg (14-40)	1.41% (95% CI 0.88-2.06%)
Excluding Mishell et al. (14-33)	1.46% (95% CI 0.89-2.16%)